James Lewis: Clinical Trials

6 trials sponsored by James Lewis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 enrolling by invitation, 1 recruiting. 3 Not applicable, 2 Phase 4, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Not applicable3Completed 1, Enrolling by invitation 1, Recruiting 1
Phase 42Completed 2
Phase 21Completed 1

Follow James Lewis: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
Partial enteral nutrition - orally consumed formula - Crohn's Disease, Active
Not applicableEnrolling by invitationJames Lewis802026-11-032026-11-17
Healthy Volunteers Enteral Nutrition Study (HEN)
Kate Farms Peptide 1.5, Crohn's disease exclusion diet - Enteral Nutrition's Effect on the Gut
Not applicableRecruitingJames Lewis252026-06-172026-08-06
Controlled Feeding Experiment
High fat diet - Effect of Diet on Microbiome Composition
Not applicableCompletedJames Lewis102009-07-012013-06-25
Dose Escalation and Remission (DEAR)
mesalamine - Ulcerative Colitis
Phase 4CompletedJames Lewis1192008-09-012015-05-05
Gene Regulation by Thiazolidinediones
Rosiglitazone - Inflammatory Bowel Disease
Phase 4CompletedJames Lewis122007-10-012016-08-01
A Trial of Rosiglitazone for Ulcerative Colitis
Rosiglitazone, Placebo - Ulcerative Colitis, Inflammatory Bowel Disease
Phase 2CompletedJames Lewis1052002-09-012018-01-16

Conditions studied

Inflammatory Bowel Diseases (3)  ·  Colitis, Ulcerative (2)  ·  Colitis (1)  ·  Crohn Disease (1)  ·  Motor Activity (1)  ·  Ulcer (1)

Interventions

Rosiglitazone (2)  ·  Diet, High-Fat (1)  ·  Mesalamine (1)

Countries

United States (6)

Top investigators

James D Lewis, MD, MSCE (4)

Results publications

PMID 18325386, PMID 18623174, PMID 24793028

NIH funding

R01DK059961 (2), K24DK078228 (1), UH2DK083981 (1)